Challenges in developing a cross-serotype rhinovirus vaccine
File(s)
Published version
Author(s)
Glanville, N
Johnston, SL
Type
Journal Article
Abstract
A great burden of disease is attributable to human rhinovirus (HRV) infections which are the major cause of the common cold, exacerbations of both asthma and chronic obstructive pulmonary disease (COPD), and are associated with asthma development. Despite this there is currently no vaccine for HRV. The first vaccine studies showed some promise in terms of serotype-specific protection against cold symptoms, but antigenic heterogeneity amongst the >150 HRVs has been regarded as a major barrier to effective vaccine development and has resulted in little progress over 50 years. Here we review those vaccine studies conducted to date, discuss the difficulties posed by antigenic heterogeneity and describe some recent advances in generating cross-reactive antibodies and T cell responses using peptide immunogens.
Date Issued
2015-03-29
Citation
Current Opinion in Virology, 2015, 11, pp.83-88
ISSN
1879-6257
Publisher
Elsevier
Start Page
83
End Page
88
Journal / Book Title
Current Opinion in Virology
Volume
11
Copyright Statement
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)